Bill cites fakes dangers, ups penalties

Increased jail time and financial penalties for drug counterfeiters are the subject of a bill proposed by U.S. legislators. The Counterfeit Drug Penalty Enhancement Act is a bipartisan proposal encompassing the manufacture, trafficking and sales of fake drugs.

The proposed legislation would boost the maximum prison sentence to 20 years for first-time individual offenders, with a maximum fine of $4 million, reports Securing Pharma. For repeat offenders, the fine can reach $8 million. Fines for institutions can reach $10 million for a first offense, $20 million for repeats.

Sen. Patrick Leahy (D-VT) is sponsoring the legislation in the Senate and is joined by Sens. Chuck Grassley (R-IA), Michael Bennet (D-CO) and Richard Blumenthal (D-CT). Reps. Patrick Meehan (R-PA) and Linda Sanchez (D-CA) are leading the effort in the House. The legislation comes in response to recommendations made by the U.S. Intellectual Property Enforcement Coordinator and the Obama administration's Counterfeit Pharmaceutical Inter-agency Working Group, Leahy notes in a release.

Leahy says drug counterfeiting penalties--long bemoaned by pharma companies--are the same as those for trafficking consumer goods, which pose no physical threat to people. "This legislation will raise those penalties to a level that meets the severity of the offense."

PhRMA has already praised the lawmakers for introducing the legislation. "In the U.S., the jail sentence for a counterfeiting crime is typically three years, but we believe that more significant criminal penalties, including as much as 20 years imprisonment, is more appropriate for such a potentially deadly crime."

- read Leahy's statement
- check out PhRMA's release
- get more from Securing Pharma

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.